TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02663700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: Four tablets of 50mg each, totaling 200mg will be given in a single calendar day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT05218876

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low- to moderate intensity strength and endurance training
Description: Combination of strength and endurance training with low- to moderate intensity during chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity strength and endurance training
Description: Combination of strength and endurance training with high intensity during chemotherapy
Study: NCT01700803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone Iodine 10% vand cesarean section wound infections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone Iodine 7.5% vand cesarean section wound infections
Study: NCT04236284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based tDCS
Description: tDCS is a non-invasive neuromodulation technique that has been used to improved cognitive functions. It will be administered with a constant current intensity of 2 mA57 for 20 min per session/ 10 sessions total daily for 2 weeks (Monday to Friday). The device is a Soterix 1x1 tDCS mini-CT Stimulator (Soterix Medical Inc., NY) with headgear and 5 _ 7 cm saline-soaked surface sponge electrodes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is a treatment for PTSD that includes the following components: a) psycho-education about the common reactions to traumatic events and presentation of the treatment rationale (sessions 1 and 2), b) repeated in vivo exposure to traumatic stimuli (in vivo exercises are assigned as homework during sessions 3 through 11), c) repeated, prolonged, imaginal exposure to traumatic memories (imaginal exposure is implemented during sessions 3 through 11; patients listen to session audiotapes for homework between sessions), and d) relapse prevention strategies and further treatment planning (session 12).
Study: NCT02453607

Intervention type: DRUG
Intervention: Infliximab
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.

Intervention type: DRUG
Intervention: Infliximab
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.

Intervention type: DRUG
Intervention: thiopurine
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
Study: NCT04176913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUCAR-20S CAR-T cells
Description: An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
Study: NCT04213443

Intervention type: OTHER
Intervention: Analysis of a patient registry
Description: Analysis of a patient registry.
Study: NCT02709746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day
Description: 10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg/day
Description: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 mg/day
Description: 20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablet
Study: NCT01459926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211
Description: Once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily
Study: NCT03758469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: Sequence 1: Intravenously infuse 0.4 mg/kg HSK3486 in the morning on an empty stomach. Complete infusion within 1 min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin , HSK3486
Description: Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
Study: NCT00546442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformine
Description: 850-2550 mg/daily for 48 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of metformine
Description: 850-2550 mg/daily for 48 weeks
Study: NCT01224379

Intervention type: DEVICE
Group type: OTHER
Intervention: Topping off system
Description: The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion).

Intervention type: DEVICE
Group type: OTHER
Intervention: monosegmental PLIF
Description: The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
Study: NCT03098316

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics analysis of patient samples
Description: Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics analysis of patient samples
Description: Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Metabolomics analysis of patient samples
Description: Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
Study: NCT02191826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM0226
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM0226
Description: Oral
Study: NCT02089347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed
Description: 0.5 mL, intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus toxoids adsorbed
Description: 0.1 mL, Subcutaneously
Study: NCT04158765

Intervention type: OTHER
Intervention: DNeasy Tissue Kit (QIAGEN Inc., Mississauga, Ontario, Canada) and PCR- based assay (TRAPeze Telomerase Detection Kit; Millipore, Billerica, MA).
Description: DNA will be extracted from sperm using the DNeasy Tissue Kit and Telomerase activity in samples will be measured using a PCR- based assay.
Study: NCT00458237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is being administered orally 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is being administered orally 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is being administered orally 7 days per week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
Study: NCT01088087

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: colostrum
Description: colostrum, 2g, 2 times a day, for 3 weeks
Study: NCT02873234

Intervention type: DRUG
Intervention: Traditional Chinese Medicine
Description: Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.

Intervention type: DRUG
Intervention: Traditional Chinese Medicine
Description: Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.

Intervention type: DRUG
Intervention: Antidepressants
Description: Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.

Intervention type: DRUG
Intervention: Antidepressants
Description: Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
Study: NCT03069703

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: one dose of PCV13 at D0 (arm A) or two double doses at D0 and D7 (Arm B) or one quadruple dose at D0 (arm C)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23
Description: one dose of PPV23 at M5
Study: NCT01607658

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo intranasal gel administered prn, 2-8 hours before a planned sexual event

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose TBS-2
Description: Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose TBS-2
Description: Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose TBS-2
Description: High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
Study: NCT02000921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC cigarettes
Description: Modified risk tobacco product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC cigarettes
Description: Modified risk tobacco product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combusted Products
Description: Options for combusted tobacco products include cigars, cigarillos, and little cigars, .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combusted Products
Description: Options for combusted tobacco products include cigars, cigarillos, and little cigars, .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted products
Description: Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted products
Description: Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-combusted products
Description: Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CN cigarettes
Description: Experimental cigarettes with conventional nicotine content.
Study: NCT02193841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage with puncture (C & P)
Description: A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage with puncture (C & P)
Description: A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Curette
Description: A small surgical instrument with a rounded edge designed for scraping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Curette
Description: A small surgical instrument with a rounded edge designed for scraping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vitoss morsels
Description: A bone substitute intended for use as a filler for voids or gaps in bones
Study: NCT02700399

Intervention type: DEVICE
Group type: OTHER
Intervention: Erigo® Hocoma
Description: Robotics assisted tilt table, without functional electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Erigo® Hocoma
Description: Robotics assisted tilt table, without functional electrical stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional tilt table from Rehab-Care
Description: Traditional tilt table

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional tilt table from Rehab-Care
Description: Traditional tilt table
Study: NCT02415972

Intervention type: OTHER
Intervention: Ultrasound perfusion imaging
Description: Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
Study: NCT03069703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PPV23
Description: one dose of PPV23 at M5

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV23
Description: one dose of PPV23 at M5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
Study: NCT04687059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PQ Grass
Description: Suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PQ Grass
Description: Suspension for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Option 1
Description: Suspension for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Option 2
Description: Solution for injection
Study: NCT04339959

Intervention type: OTHER
Intervention: Remote Assessment of Physical Function with Direct Observation
Description: An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.

Intervention type: OTHER
Intervention: Remote Assessment of Physical Function with Direct Observation
Description: An android tablet with Wi-Fi and cellular will be used to compare videoconferencing with face-to-face assessment of 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.

Intervention type: OTHER
Intervention: Remote Assessment of Physical Function
Description: An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.

Intervention type: OTHER
Intervention: Remote Assessment of Physical Function
Description: An android tablet with Wi-Fi and cellular will be mailed to study participants to remotely assess 2 timed, physical performance tests. The physical performance tests include the 30-second chair stand test (30s-CST) and the Timed Up \& Go (TUG) test. The TUG test is measured as the time to stand from a standard arm chair, walk 10 feet, turn around, return to start and sit down. The 30s-CST is measured as the number of times a person comes to a full standing position from a chair in 30 seconds, as quickly as possible, without using ones' hands.
Study: NCT03241108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0101
Description: Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01205334

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous CMV-specific CTL
Description: CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.~At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion.
Study: NCT03257943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Lotion, 0.5%
Description: Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKLICE (ivermectin) Lotion, 0.5%
Description: SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of the Test product
Description: Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
Study: NCT01559441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot Juice with oral fat load
Description: 140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate control drink with oral fat load
Description: 140 mL (low-nitrate) carbohydrate control drink
Study: NCT03620448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bCPAP Arm
Description: bCPAP (Rice 360◦c low cost bCPAP device)

Intervention type: OTHER
Group type: OTHER
Intervention: Oxygen Arm
Description: Oxygen therapy from oxygen cylinders
Study: NCT03030521

Intervention type: DIAGNOSTIC_TEST
Intervention: the aortic delamination test
Description: The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.

Intervention type: DIAGNOSTIC_TEST
Intervention: the aortic delamination test
Description: The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
Study: NCT03530293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: non-active dosage form
Study: NCT04424979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High power prisms
Description: High power prisms designed to shift images from blind areas into portions of the wearer's remaining, seeing, field of vision
Study: NCT03805334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Touchpoints
Description: Touchpoints are worn on either the wrists or ankles. They deliver a low level vibration in an alternating fashion to the skin.
Study: NCT04215835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole then misoprostol
Description: Drug: Letrozole 2.5mg total dose 7.5 mg per day for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo then misoprostol
Description: Drug: Placebo placebo for 3 days~Drug: Misoprostol Misoprosrol 800mcg will be given to all patients for induction of abortion